Tiny study aims to unlock why dupilumab works for eczema
NCT ID NCT05858619
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looks at how dupilumab, an approved eczema drug, changes immune cells in the skin. Researchers will take skin samples from 15 adults with moderate-to-severe eczema before and after treatment. The goal is to understand the molecular changes that lead to improvement, not to test if the drug works.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Dupilumab
- What this could lead to
- If successful, this could help doctors predict which eczema patients will benefit most from dupilumab and why.
- What could go wrong
- This is a very small, early-phase study with only 15 participants, so results may not apply to everyone. It is designed to gather information, not to prove a new treatment works.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of California, San Francisco
RECRUITINGSan Francisco, California, 94143, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new injection calm severe eczema when creams fall short?
- Can a new biologic calm severe eczema?
- Can a daily probiotic soothe colicky babies and calm eczema?
- Can a new injection match an existing eczema treatment?
- Can Real-World data unlock better skin disease care?
- Can a meditation app soothe teen eczema?